EyePoint Announces Strategic Prioritization
Key Highlights
- ➤LUCIA Phase 3 missed wet AMD non-inferiority primary endpoint despite vision improvements.
- ➤EyePoint (EYPT) will end pivotal wet AMD trials before completing their second year.
- ➤Workforce reduction affects approximately 53% of employees, primarily during Q4 2026.
- ➤Strategic prioritization targets DME, with Phase 3 topline data expected in Q4 2027.
- ➤Annualized savings estimated at approximately $30 million; one-time charges near $9 million.
Expert Statements
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
“Decisions involving a reduction in our workforce are exceptionally difficult, and we extend our deepest gratitude to our departing colleagues for their dedication and meaningful contributions. While the inherent volatility of clinical development introduces profound hurdles, our core mission remains steadfast: navigating these challenges to deliver durable therapies that can truly improve the lives of patients”
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
“The strategic prioritization enables us to focus on our next milestone, the pivotal Phase 3 readout in DME that will evaluate DURAVYU’s potential to offer a durable, long-term therapeutic option that safely reduces the overall injection burden for patients. The DME program is supported by the positive Phase 2 VERONA data showing sustained visual acuity and over 70% of patients supplement-free for six months. DURAVYU also provides continuous intracellular delivery targeting pan-VEGF, PDGF, and IL-6 pathways to address both vascular and inflammatory disease drivers, which makes DURAVYU a particularly compelling potential treatment given the nature of this disease.”
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for DURAVYU™ in diabetic macular edema (DME). This strategic realignment follows today’s topline readout from the Phase 3 LUCIA study of DURAVYU in wet AMD, which did not meet its primary endpoint of non-inferiority, despite vision improvements, and despite meeting key secondary endpoints including reduction in treatment burden, supplement-free rates, anatomic control, and safety with redosing.
To preserve capital and maximize shareholder value, the Board of Directors has approved a plan to reduce the Company's workforce by approximately 53% of employees and to conclude the pivotal Phase 3 wet AMD trials early, without full completion of the second year of each trial. EyePoint plans to prioritize the development of DURAVYU for the potential treatment of DME, which is expected to read out pivotal Phase 3 topline data in the fourth quarter of 2027.
Get started
Create a free account to read the full story.